Bone Marrow Derived Stem Cell Ophthalmology Treatment Study II

Who is this study for? Patients with Retinal and Optic Nerve Damage or Disease
Status: Recruiting
Location: See all (4) locations...
Intervention Type: Procedure
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

This study will evaluate the use of autologous bone marrow derived stem cells (BMSC) for the treatment of retinal and optic nerve damage or disease.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Have objective, documented damage to the retina or optic nerve unlikely to improve OR

• Have objective, documented damage to the retina or optic nerve that is progressive AND have less than or equal to 20/30 best corrected central visual acuity in one or both eyes AND/OR an abnormal visual field in one or both eyes.

• Be at least 3 months post-surgical treatment intended to treat any ophthalmologic disease and stable.

• If under current medical therapy ( pharmacologic treatment) for a retinal or optic nerve disease be considered stable on that treatment and unlikely to have visual function improvement ( for example, glaucoma with intraocular pressure stable on topical medications but visual field damage ).

• Have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure.

• Be over the age of 18

• Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure.

• Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health.

Locations
United States
Connecticut
MD Stem Cells
RECRUITING
Westport
Florida
MD Stem Cells
RECRUITING
Coral Springs
Other Locations
Austria
MD Stem Cells Kobinia Med
RECRUITING
Vienna
United Arab Emirates
The Saudi-German Hospital
RECRUITING
Dubai
Contact Information
Primary
Steven Levy, MD
stevenlevy@mdstemcells.com
203-423-9494
Backup
Steven Levy, MD
203-423-9494
Time Frame
Start Date: 2016-01
Estimated Completion Date: 2027-07-31
Participants
Target number of participants: 500
Treatments
Other: Arm 1
BMSC provided retrobulbar, subtenon and intravenous for one or both eyes
Sponsors
Leads: MD Stem Cells

This content was sourced from clinicaltrials.gov

Similar Clinical Trials

We couldn't find any related articles check for more on the main search page.